Patents by Inventor Alan Kozikowski

Alan Kozikowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210139438
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed.
    Type: Application
    Filed: November 16, 2020
    Publication date: May 13, 2021
    Inventors: Alan Kozikowski, Irina Gaisina
  • Patent number: 10973819
    Abstract: Embodiments concern methods and small molecule compositions for selectively inhibiting RAD51-mediated D-loop formation while preserving RAD51's ability to form nucleoprotein filaments. The selective RAD51 D-loop formation activity inhibitors DNA repair while minimizing replication-associated toxicity in normal tissue.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 13, 2021
    Assignee: The University of Chicago
    Inventors: Philip Connell, Wei Lv, Brian Budke, Alan Kozikowski
  • Patent number: 10934255
    Abstract: Compounds that inhibit histone (HDACI) and/or activate Nrf2 and HIF, and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC and/or activation of Nrf2 and HIF provide a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: March 2, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Irina Gaisina, Alan Kozikowski
  • Patent number: 10836733
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: November 17, 2020
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Alan Kozikowski, Irina Gaisina
  • Publication number: 20200039933
    Abstract: Compounds that inhibit histone (HDACI) and/or activate Nrf2 and HIF, and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC and/or activation of Nrf2 and HIF provide a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
    Type: Application
    Filed: April 25, 2018
    Publication date: February 6, 2020
    Inventors: Irina Gaisina, Alan Kozikowski
  • Patent number: 10456394
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: October 29, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Alan Kozikowski, Sida Shen, Joel Bergman, Irina Gaisina
  • Patent number: 10407381
    Abstract: Disclosed are 2-phenyl-cyclopropylmethanamines which are selective 5-HT(2C) receptor agonists and are used in the treatments of diseases and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: September 10, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Alan Kozikowski, Jianjun Cheng
  • Publication number: 20190255046
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.
    Type: Application
    Filed: February 15, 2017
    Publication date: August 22, 2019
    Applicant: The Board of Trustees of the University of Illinos
    Inventors: Alan KOZIKOWSKI, Sida SHEN, Joel BERGMAN, Irina GAISINA
  • Publication number: 20190083491
    Abstract: Embodiments concern methods and small molecule compositions for selectively inhibiting RAD51-mediated D-loop formation while preserving RAD51's ability to form nucleoprotein filaments. The selective RAD51 D-loop formation activity inhibitors DNA repair while minimizing replication-associated toxicity in normal tissue.
    Type: Application
    Filed: March 2, 2017
    Publication date: March 21, 2019
    Inventors: Philip Connell, Wei Lv, Brian Budke, Alan Kozikowski
  • Publication number: 20190023670
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed.
    Type: Application
    Filed: August 31, 2016
    Publication date: January 24, 2019
    Inventors: Alan Kozikowski, Irina Gaisina
  • Publication number: 20180265453
    Abstract: Disclosed are 2-phenyl-cyclopropylmethanamines which are selective 5-HT(2C) receptor agonists and are used in the treatments of diseases and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders.
    Type: Application
    Filed: January 27, 2016
    Publication date: September 20, 2018
    Inventors: Alan Kozikowski, Jianjun Cheng
  • Patent number: 9956192
    Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: May 1, 2018
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Board of Trustees of The University of Illinois
    Inventors: Eduardo M. Sotomayor, Joel Bergman, Alan Kozikowski, Karrune Veeraprasert Woan, Alejandro V. Villagra
  • Publication number: 20170044100
    Abstract: The present invention provides novel indoleamide compounds for treating tuberculosis, including drug-resistant M-tuberculosis, compositions comprising the indoleamides and methods of using the indoleamides in conjunction with other biologically active agents for the treatment of tuberculosis in a subject in need thereof.
    Type: Application
    Filed: April 22, 2015
    Publication date: February 16, 2017
    Inventors: William R. Bishai, Shichun Lun, Haidan Guo, Alan Kozikowski, Oluseye Onajole, Jozef Stec
  • Publication number: 20170035710
    Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
    Type: Application
    Filed: August 8, 2016
    Publication date: February 9, 2017
    Inventors: Eduardo M. Sotomayor, Joel Bergman, Alan Kozikowski, Karrune Veeraprasert Woan, Alejandro V. Villagra
  • Patent number: 9409858
    Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: August 9, 2016
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Board of Trustees of the University of Illinois
    Inventors: Eduardo M. Sotomayor, Joel Bergman, Alan Kozikowski, Karrune Veeraprasert Woan, Alejandro V. Villagra
  • Patent number: 9249087
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: February 2, 2016
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Alan Kozikowski, Jay H. Kalin, Kyle V. Butler, Joel Bergman, Wayne W. Hancock
  • Publication number: 20150056213
    Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
    Type: Application
    Filed: March 7, 2013
    Publication date: February 26, 2015
    Inventors: Eduardo M. Sotomayor, Joel Bergman, Alan Kozikowski, Karrune Veeraprasert Woan, Alejandro V. Villagra
  • Patent number: 8754132
    Abstract: Highly selective 5-HT(2C) receptor agonists receptors are disclosed. The 5-HT(2C) receptor agonists are used in the treatments of disease and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: June 17, 2014
    Assignees: The Board of Trustees of the University of Illinois, The University of North Carolina at Chapel Hill
    Inventors: Alan Kozikowski, Bryan Roth, Andreas Svennebring, Sung Jin Cho
  • Patent number: 8748451
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: June 10, 2014
    Assignee: The Board of Trustees of The University of Illinois
    Inventors: Alan Kozikowski, Kyle Vincent Butler, Jay Hans Kalin
  • Patent number: RE47009
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: August 28, 2018
    Assignees: THE CHILDREN'S HOSPITAL OF PHILADELPHIA, THE TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Alan Kozikowski, Jay Hans Kalin, Kyle Vincent Butler, Joel Bergman, Wayne W. Hancock